148 related articles for article (PubMed ID: 8442771)
1. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats.
Brouwer KL; Hall ES; Pollack GM
Biochem Pharmacol; 1993 Feb; 45(3):735-42. PubMed ID: 8442771
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions.
Booth CL; Pollack GM; Brouwer KL
Hepatology; 1996 Apr; 23(4):771-80. PubMed ID: 8666331
[TBL] [Abstract][Full Text] [Related]
3. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats.
Yamamura N; Imura K; Naganuma H; Nishimura K
Drug Metab Dispos; 1999 Jun; 27(6):724-30. PubMed ID: 10348803
[TBL] [Abstract][Full Text] [Related]
4. Probenecid-associated alterations in valproic acid pharmacokinetics in rats: can in vivo disposition of valproate glucuronide be predicted from in vitro formation data?
Ward ES; Pollack GM; Brouwer KL
Drug Metab Dispos; 2000 Dec; 28(12):1433-9. PubMed ID: 11095580
[TBL] [Abstract][Full Text] [Related]
5. Nonlinear elimination and hepatic concentration of conjugation-metabolite of valproate in guinea-pigs.
Yu HY; Wu MS; Shen YZ
Biopharm Drug Dispos; 1993 May; 14(4):297-312. PubMed ID: 8499581
[TBL] [Abstract][Full Text] [Related]
6. Lorazepam-valproate interaction: studies in normal subjects and isolated perfused rat liver.
Anderson GD; Gidal BE; Kantor ED; Wilensky AJ
Epilepsia; 1994; 35(1):221-5. PubMed ID: 8112251
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats.
Nakajima Y; Mizobuchi M; Nakamura M; Takagi H; Inagaki H; Kominami G; Koike M; Yamaguchi T
Drug Metab Dispos; 2004 Dec; 32(12):1383-91. PubMed ID: 15345660
[TBL] [Abstract][Full Text] [Related]
8. Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, via glucuronidation. LC/MS/MS characterization of the GSH-glucuronide diconjugates.
Tang W; Abbott FS
Chem Res Toxicol; 1996 Mar; 9(2):517-26. PubMed ID: 8839057
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacodynamics and brain distribution of E-delta 2-valproate and valproate in rats.
Semmes RL; Shen DD
Epilepsia; 1991; 32(2):232-41. PubMed ID: 2004628
[TBL] [Abstract][Full Text] [Related]
10. Concentration-dependent disposition of glucuronide metabolite of valproate.
Yu HY; Shen YZ
J Pharm Pharmacol; 2002 May; 54(5):633-9. PubMed ID: 12005358
[TBL] [Abstract][Full Text] [Related]
11. Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.
Pollack GM; Brouwer KL
J Pharmacokinet Biopharm; 1991 Apr; 19(2):189-225. PubMed ID: 2013839
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent distribution volumes of total and unbound valproate in guinea-pigs: consequence of non-linear plasma protein binding.
Yu HY; Shen YZ
Biopharm Drug Dispos; 1996 Apr; 17(3):237-47. PubMed ID: 8983398
[TBL] [Abstract][Full Text] [Related]
13. Studies on the reactivity of acyl glucuronides--III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans.
Williams AM; Worrall S; de Jersey J; Dickinson RG
Biochem Pharmacol; 1992 Feb; 43(4):745-55. PubMed ID: 1540228
[TBL] [Abstract][Full Text] [Related]
14. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect.
Dickinson RG; Harland RC; Ilias AM; Rodgers RM; Kaufman SN; Lynn RK; Gerber N
J Pharmacol Exp Ther; 1979 Dec; 211(3):583-95. PubMed ID: 390116
[TBL] [Abstract][Full Text] [Related]
15. Unbound valproate fraction in plasma and subcutaneous microdialysate in steady state and after a single dose in humans.
Lindberger M; Tomson T; Ståhle L
Ther Drug Monit; 2003 Jun; 25(3):378-83. PubMed ID: 12766568
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of valproate analogs in rats. III. Pharmacokinetics of valproic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid in the bile-exteriorized rat.
Liu MJ; Brouwer KL; Pollack GM
Drug Metab Dispos; 1992; 20(6):810-5. PubMed ID: 1362931
[TBL] [Abstract][Full Text] [Related]
17. Glucuronidation metabolic kinetics of valproate in guinea pigs: nonlinear at clinical concentration levels.
Yu HY; Shen YZ
Pharm Res; 1996 Aug; 13(8):1243-6. PubMed ID: 8865320
[TBL] [Abstract][Full Text] [Related]
18. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
Tang W; Abbott FS
Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid elimination rate and urinary excretion of its glucuronide conjugate in patients with epilepsy.
Yoshida H; Hirozane K; Kimoto H; Hayashi T; Akiyama T; Katayama H; Watanabe M; Yoshitomi H; Kamiya A
Biol Pharm Bull; 1999 Jul; 22(7):716-20. PubMed ID: 10443469
[TBL] [Abstract][Full Text] [Related]
20. Probenecid-associated alterations in valproate glucuronide hepatobiliary disposition: mechanistic assessment using mathematical modeling.
Ward ES; Pollack GM; Brouwer KL
J Pharmacol Exp Ther; 2001 Apr; 297(1):141-7. PubMed ID: 11259538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
